Sensus Healthcare, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Sensus Healthcare, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.48M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $41.81M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $24.41M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $44.53M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $27.04M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $9.58M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $27.26M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $26.43M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $20.59M | Mar 15, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.48M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $41.81M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $24.41M | Mar 5, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $20.59M | Feb 15, 2018 |
| FY2017 | Dec 31, 2016 | $14.81M | Feb 15, 2018 |
| FY2016 | Dec 31, 2015 | $10.27M | Mar 10, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.87M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $24.43M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $14.06M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $29.63M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $16.99M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $5.25M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $17.56M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $16.91M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $13.80M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $9.85M | Feb 15, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.72M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $6.65M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $485.0K | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $24.24M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $4.12M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($6.84M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($1.70M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($2.02M) | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | ($3.71M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($346.4K) | Feb 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.31M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $8.09M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($382.0K) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $14.83M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $4.12M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($8.23M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($1.97M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($2.01M) | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | ($3.72M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($363.1K) | Feb 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.78M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $4.22M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $3.68M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $3.46M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.44M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $4.16M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $6.42M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $6.26M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $5.49M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.82M | Feb 15, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.87M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $7.15M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $5.16M | Mar 5, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $528.0K | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($831.0K) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($2.15M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($1.41M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($286.0K) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($434.0K) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($2.11M) | Mar 5, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.0K | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $276.0K | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $229.0K | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $159.0K | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $128.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $359.0K | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $400.6K | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $854.8K | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $287.6K | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $286.0K | Feb 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.04M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $62.17M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $53.71M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $56.74M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $32.24M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $28.01M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $36.92M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $33.25M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $18.84M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $18.95M | Feb 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.94M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $6.34M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $4.87M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $8.67M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $6.23M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $6.51M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $8.92M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $6.79M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $7.15M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.67M | Feb 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.10M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $55.83M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $48.84M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $48.07M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $26.02M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $21.50M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $28.00M | Mar 25, 2022 |
| FY2020 | Dec 31, 2018 | $26.46M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $11.68M | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $15.27M | Mar 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.72M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $13.43M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $6.79M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $6.30M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($17.94M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($22.06M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($15.23M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($13.53M) | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | ($11.50M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($7.79M) | Feb 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.08M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $22.06M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $23.15M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $25.52M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $14.52M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $14.91M | Mar 25, 2022 |
| FY2021 | Dec 31, 2019 | $8.10M | Mar 25, 2022 |
| FY2020 | Dec 31, 2018 | $12.48M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $10.09M | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $5.04M | Mar 15, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.46M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 16.50M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 16.37M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 16.39M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 16.62M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 16.49M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | 16.49M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | 16.11M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | 13.49M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 13.55M | Feb 15, 2018 |